8-K: Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Prelude Therapeutics announces its full year 2024 financial results, highlighting clinical progress with SMARCA2 degraders and a cash runway into the second quarter of 2026.

Summary

• Prelude Therapeutics reported its full year 2024 financial results on March 10, 2025.
• The company's cash, cash equivalents, and marketable securities totaled $133.6 million as of December 31, 2024.
• Prelude anticipates this will fund operations into the second quarter of 2026.
• Research and development expenses for 2024 increased to $118.0 million from $103.4 million in the prior year.
• General and administrative expenses decreased slightly to $28.7 million from $28.9 million in the prior year.
• The net loss for 2024 was $127.2 million, or $1.68 per share, compared to $121.8 million, or $2.02 per share, for the prior year.
• PRT3789 monotherapy dose escalation is nearing completion, and combination dose escalation with docetaxel continues, with additional results expected in the second half of 2025.
• Enrollment in the Phase 1 study of PRT7732, an oral SMARCA2 degrader, is on track, with an interim data update anticipated in the second half of 2025.
• The company intends to seek a partner for future advancement of PRT2527, focusing on SMARCA2 degrader development.
• Bryant D. Lim was named the permanent Chief Financial Officer in February 2025.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive clinical progress and a solid cash position, but also acknowledges the net loss and increased R&D expenses. The focus on future milestones and potential partnerships suggests a positive outlook.

Positives

• PRT3789 has demonstrated clinical proof-of-concept with monotherapy anti-tumor activity in patients with SMARCA4-deficient cancers.
• PRT3789 in combination with docetaxel has demonstrated an acceptable safety profile.
• PRT7732 is a potent, highly selective, and orally bioavailable SMARCA2 degrader with enrollment in a Phase 1 trial progressing rapidly.
• The company's Precision ADC platform has shown potent activity of a SMARCA2/4 degrader payload when conjugated to various antibodies.
• The company has a strong cash position of $133.6 million, expected to fund operations into the second quarter of 2026.

Negatives

• The company reported a net loss of $127.2 million for the year ended December 31, 2024.
• Research and development expenses increased to $118.0 million for the year ended December 31, 2024.
• The company intends to seek a partner for future advancement of PRT2527, indicating a potential shift in focus or resource allocation.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the ability to advance product candidates, receive regulatory approvals, and fund development activities.
• Clinical trial results are inherently uncertain, and actual results may differ significantly from expectations.
• The company's ability to protect intellectual property is a risk factor.
• The company's ability to enroll eligible patients in clinical trials is a risk factor.
• The company's ability to maintain and recognize the benefits of certain designations received by product candidates is a risk factor.

Future Outlook

Prelude Therapeutics anticipates its existing cash, cash equivalents, and marketable securities will fund operations into the second quarter of 2026. The company plans to share data throughout the year from ongoing dose escalation and combination studies with PRT3789, and the first clinical data from the ongoing clinical trial of PRT7732. An update on the emerging discovery pipeline is expected in the first half of 2025.

Management Comments

• Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, stated that 2024 was a productive year for Prelude, highlighted by efforts to advance the first ever highly selective SMARCA2 degraders to treat cancer patients who harbor SMARCA4 deleterious mutations.
• Vaddi noted that these patients have a very poor clinical prognosis and are faced with limited treatment options.
• Vaddi added that Prelude was the first to establish that selectively targeting SMARCA2 in patients with SMARCA4-deficient cancers could represent an important new class of therapy.
• Vaddi stated that SMARCA2 degraders appear generally safe and well-tolerated in clinical trials and have anti-tumor activity in several types of SMARCA4-deficient cancers.
• Vaddi said that the company looks forward to sharing data throughout the year from ongoing dose escalation and combination studies with PRT3789, and the first clinical data from the ongoing clinical trial of PRT7732.
• Vaddi noted that the research and development organization was incredibly productive throughout 2024, continuing the mission to deliver new precision oncology medicines for patients with significant unmet need.

Industry Context

Prelude Therapeutics is focused on precision oncology, a growing field that aims to develop targeted therapies based on the genetic characteristics of a patient's cancer. The company's focus on SMARCA2 degraders addresses a specific unmet need in patients with SMARCA4-deficient cancers, a particularly aggressive form of the disease. The development of Precision ADCs further expands the company's reach by targeting a broader range of cancers, independent of SMARCA4 mutation status.

Comparison to Industry Standards

• The company's approach of developing SMARCA2 degraders is novel, as it targets a specific vulnerability in SMARCA4-deficient cancers.
• Other companies in the precision oncology space include Roche (developing targeted therapies based on genomic profiling), Novartis (focused on targeted therapies and immunotherapies), and AstraZeneca (developing targeted therapies and ADCs).
• Prelude's development of Precision ADCs aligns with the industry trend of developing more targeted and effective ADC therapies.
• The company's cash runway into the second quarter of 2026 is comparable to other clinical-stage biotech companies, providing sufficient funding for ongoing clinical trials and research activities.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and clinical updates provide information for investment decisions.
• Employees: The company's progress and financial stability impact job security and opportunities.
• Patients: The development of new therapies offers potential treatment options for cancer patients with unmet needs.
• Partners: The company's collaborations and partnerships are important for advancing its pipeline and expanding its reach.

Next Steps

• Present additional results from PRT3789 monotherapy and combination cohorts in the second half of 2025.
• Provide an interim data update for PRT7732 in the second half of 2025.
• Advance the first Precision ADC candidate in partnership with AbCellera in 2025.
• Report Phase 1 monotherapy clinical results for PRT2527.
• Report Phase 1 docetaxel combination interim data for PRT3789.
• Advance the next first-in-class, novel small molecule candidate(s) from the Discovery Engine.

Key Dates